{"id":"NCT02282020","sponsor":"AstraZeneca","briefTitle":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","officialTitle":"A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-06","primaryCompletion":"2018-10-10","completion":"2022-07-19","firstPosted":"2014-11-04","resultsPosted":"2019-12-02","lastUpdate":"2022-07-26"},"enrollment":266,"design":{"allocation":"RANDOMIZED","model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity"],"interventions":[{"type":"DRUG","name":"OLAPARIB","otherNames":[]},{"type":"DRUG","name":"Single agent chemotherapy","otherNames":[]}],"arms":[{"label":"1/OLAPARIB","type":"EXPERIMENTAL"},{"label":"2/CHEMOTHERAPY","type":"ACTIVE_COMPARATOR"}],"summary":"Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy. Patient should have received at least 2 prior lines of platinum based chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.","primaryOutcome":{"measure":"Objective Response Rate (ORR)","timeFrame":"RECIST follow-up assessments performed every 8 weeks (±1 week), up to 48 weeks, then every 12 weeks (±1 week) from randomisation, assessed from date of first patient randomised to data cut off: 10Oct2018 (approx. 3 years 8 months)","effectByArm":[{"arm":"Olaparib 300 mg BID","deltaMin":109,"sd":null},{"arm":"Single Agent Chemotherapy","deltaMin":37,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":6},"locations":{"siteCount":94,"countries":["United States","Argentina","Belgium","Brazil","Canada","Czechia","Hungary","Israel","Italy","Mexico","Poland","South Korea","Spain"]},"refs":{"pmids":["39668137","32530768","32530766","32073956"],"seeAlso":["http://emergingmed.com/networks/AstraZeneca","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00010&amp;attachmentIdentifier=041c3c95-2c81-475b-ae11-1769903a7112&amp;fileName=20190614_SOLO-3_d0816c00010_Protocol_Amendment-v4_20Dec17_Final_Redacted_(1).pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00010&amp;attachmentIdentifier=4ef96d32-3bc9-474b-8bcf-0c6fd80190aa&amp;fileName=20190614_AZ_SOLO-3_Statistical_Analysis_Plan_v4_30-Oct-2018_Final_Redacted_(1).pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00010&amp;attachmentIdentifier=0e755241-5571-4243-b9f4-92b1001d85b3&amp;fileName=d0816c00010-add2-CSRsynopsis-redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":178},"commonTop":["Nausea","Anaemia","Fatigue","Vomiting","Diarrhoea"]}}